Kopran Ltd Share Price

Overview

Kopran Ltd share price is currently ₹190.93, down by - ₹1.83 (0.95%) from its previous closing price of ₹192.76. The share price has declined -4.45% over the past month and gained 17.13% over the past year. The stock's 52-week low and high are ₹105.65 and ₹215.44, respectively. Kopran Ltd has a market capitalisation of ₹ 950.00 Cr. The share price was last updated on 25 Aug 2026, 03:29 PM IST.

Kopran Ltd
Kopran Ltd
KOPRAN
 0.00
- 1.83
0.95%
Healthcare
 0.00(%)1D

Updated: 25 Aug 2026, 03:29:52 pm IST

Market Data

Open Price

 192.95

Prev. Close

 192.76
 186.39

Day Low

 193.47

Day High

 105.65

52 Week Low

 215.44

52 Week High

HealthcarePharmaceuticals & Drugs
CategorySmall Cap

Fundamentals

Quick Bite

Price To Earnings Ratio

36.93

Sector PE

42.03

PB Ratio

1.74

Sector PB

5.82

EPS

5.17

Dividend Yield

2.78

Today's Volume

67.186 K

5 Day Avg. Volume

115.723 K

PEG Ratio

-1.11

Market Cap.

₹ 950.00 Cr.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

ActionsEx-DateRecord-Date
DividendsFinal Dividend of 30% at ₹3/Share
11-Aug-202611-Aug-2026
DividendsFinal Dividend of 30% at ₹3/Share
04-Sep-202504-Sep-2025
DividendsFinal Dividend of 30% at ₹3/Share
02-Sep-202403-Sep-2024

Mutual Fund Ownership

Mutual Fund Holder
Jun 26
Shares held
Jul 26
Shares held
Motilal Oswal BSE Healthcare ETF726
741
(2.07%)
Bandhan BSE Healthcare Index Fund - Regular Plan - Growth371
398
(7.28%)

About Kopran Ltd 👋

Kopran Limited is an India-based pharmaceutical company. The Company is primarily engaged in the business of manufacturing of formulation (finished dosage form) and active pharmaceutical ingredients (API). Its formulations product categories include penicillin-based finished oral dosage forms and non-penicillin-based finished oral dosage forms. The Company's penicillin-based finished oral dosage forms include amoxycillin, ampicillin, cloxacillin, amoxy clauv, flucloxacillin, and phenoxy methyl penicillin. Its non-penicillin-based finished oral dosage forms include macrolides, cardiovascular, anti-helmentics, antihistamine, anti-diabetic, pain management, gastroenterology, and respiratory. It has a portfolio, producing over 100 dosage forms. These include tablets, capsules, dry powder, suspension and injectables. Its subsidiary, Kopran Research Laboratories Ltd, manufactures a range of APIs, including Atenolol and Sterile Carbapenems.

News & Events

Frequently Asked Questions

What is the share price of Kopran Ltd?

What is the market cap of Kopran Ltd?

Should I buy Kopran Ltd stock now?

What is the 52 week high and low of Kopran Ltd?

Is the Kopran Ltd stock good to buy?

Is Kopran Ltd a good buy for the long term?

Is Kopran Ltd overvalued or undervalued?

What is the PE and PB ratio of Kopran Ltd?

Start Now